Evidence strength for the context described on this page.
PEPTIDE ATLAS / ENERGY & LONGEVITY / EPITALON
Not FDA-approvedInsufficient
Epitalon
ALSO KNOWN ASEpithalon · AEDG peptide
A tetrapeptide marketed for telomeres, sleep and longevity without reliable clinical proof.
01CATEGORYEnergy & longevity
02REGULATORY STATUSNot FDA-approved
03COMMON ROUTEHistorically intramuscular or intranasal; modern products are marketed injectable, nasal or oral
04DOSE BASISLimited human literature + reported use
HOW TO USE THIS PAGE
Read the profile in the order that protects the decision.
- 01Verify what it is
Confirm the exact molecule, route, regulatory lane and actual human evidence.
- 02Read limits before dose
Unsupported claims, contraindications and uncertainty come before any protocol.
- 03Build the monitoring plan
Define the target, baseline checks, reassessment point and stop rules with a qualified clinician.
This peptide does not have an FDA-approved product or dose for the claims described here. Research dosing and vendor protocols are not consumer prescribing guidance.
RESEARCH PASSPORT
The five facts to know first.
REVIEWED
JULY 2026
Status is product-, formulation- and indication-specific.
Trial, label or reported-practice basis is always named.
Official labels, regulators, trials and indexed literature where available.
Peptide hormones, growth factors and related substances may be prohibited.
Check Global DRO ↗OVERVIEW
What Epitalon is.
A synthetic tetrapeptide associated with pineal-peptide research. Claims often reference telomerase, circadian biology or lifespan but the human evidence base is limited and difficult to generalize.
HOW IT IS THOUGHT TO WORK
Proposed to affect gene regulation, circadian signaling and telomerase activity; these mechanisms are not established clinical outcomes.
EFFECTS & EVIDENCE
What the evidence supports—and what it does not.
- No established human longevity or sleep benefit
- Telomere extension that improves health
- Longer lifespan
- Treatment of insomnia
- A safe injection cycle
Evidence grade: Insufficient. For an approved drug, “high” refers only to its labeled indication—not every off-label or wellness claim.
DOSAGE CONTEXT
Best available dosing range.
Limited human literature + reported useBest available limited-human ranges: 0.5 mg daily for 20 days in some studies; evidence reviews also report 5–10 mg intramuscularly daily for 10–20 days or 10–30 mg intranasally daily for 20–30 days. Modern clinics commonly use the 5–10 mg daily, 10–20 day cycle. These schedules are not FDA approved, and compound identity is not consistent across all historical studies.
BEST AVAILABLE GENERIC RANGE
Men and women.
The basis is named above. Reported-use ranges describe what clinics or communities publish; they are not proof of safety, efficacy, legality or product quality.
- Schedule in that source context
- Often described as a 10–20 day course, repeated only after a 4–6 month break; intranasal historical schedules differed.
- How to interpret it
- Do not treat this as a standardized protocol. Reviews flag inconsistent naming between Epitalon and pineal extracts, small regional studies and uncertain translation of historical doses to modern products.
ACTUAL HUMAN DOSES REPORTED IN THE RECORD
Research regimens may use different routes, diagnoses, formulations and monitoring. They cannot automatically be converted into a general protocol.
- Selected older human studies: 0.5 mg daily for 20 days.
- Evidence summaries of historical practice: 5–10 mg intramuscularly daily for 10–20 days or 10–30 mg intranasally daily for 20–30 days, often followed by a 4–6 month pause.
- Route
- Historically intramuscular or intranasal; modern products are marketed injectable, nasal or oral
- Duration
- Reported courses: 10–30 days with multi-month pauses; no validated longevity course
- Men & women
- No validated sex-specific protocol. Men and women are generally given the same reported milligram range despite limited evidence.
Clinician verification required. Always double-check the exact molecule or salt, concentration, route, volume, schedule, indication, patient-specific contraindications, interactions and applicable law with the prescribing clinician and dispensing pharmacy. A disclaimer does not make an unapproved product FDA-approved, and a reported-use range is not a prescription.
MONITORING
What should be tracked.
- Commercial telomere testing does not establish efficacy or safety
SAFETY
Risks, red flags and reasons to avoid it.
- FDA notes insufficient safety information
- Immunogenicity, aggregation and impurities
- Unknown effects on cell growth
- Product-identity and sterility risk
- Self-injection
- Active or recent cancer
- Pregnancy
- Using it to replace evidence-based insomnia care
Stop and seek careGet urgent medical help for trouble breathing, facial or throat swelling, chest pain, fainting, severe persistent abdominal pain, neurologic changes, severe hypoglycemia, uncontrolled vomiting or a prolonged painful erection.
CLINICIAN VISIT CHECKLIST
Six questions worth bringing with you.
Molecule or analog, salt, concentration, route, manufacturer or compounder, lot and beyond-use date.
Name the diagnosis or target, how it will be measured and the realistic time to reassess.
Ask how it compares with FDA-approved, lower-risk or better-studied alternatives.
Label, human trial, specialty guideline or clinic convention—and whether that route and formulation match.
Baseline checks, follow-up measures, interactions, pregnancy considerations and symptoms that mean stop.
Pharmacy license, prescription, identity/potency testing, sterility controls and who handles a product complaint.
Do not improvise reconstitution or convert “units” without the exact concentration. Mixing, storage and beyond-use instructions are product-specific; confirm them with the dispensing pharmacy.
PRIMARY SOURCES
Read the record yourself.
We prioritize official prescribing information, FDA regulatory material, registered trials and indexed biomedical literature. A source supports the specific statement beside it—not every claim made about the molecule.
PRODUCTS & TREATMENT ACCESS
There is no product we can responsibly recommend.
Gray-market and some compounded channels; not FDA-approved.
A telomerase claim can sound like a direct measurement of aging. It is not proof of a favorable health outcome.
Evidence before affiliate revenue.
We do not rank or sell unapproved research peptides. Use the Atlas to discuss safer, evidence-backed alternatives with a qualified clinician.
Explore evidence-backed options →NEXT STEP